171 related articles for article (PubMed ID: 19656567)
1. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
2. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Terpos E
Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
[No Abstract] [Full Text] [Related]
4. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.
Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F
Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
Hongming H; Jian H
Leuk Res; 2009 Jan; 33(1):115-22. PubMed ID: 18778854
[TBL] [Abstract][Full Text] [Related]
7. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
9. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
[TBL] [Abstract][Full Text] [Related]
11. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
[TBL] [Abstract][Full Text] [Related]
14. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
15. Management of relapsed and relapsed refractory myeloma.
Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
17. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts.
Viereck V; Siggelkow H; Tauber S; Raddatz D; Schutze N; Hüfner M
J Cell Biochem; 2002; 86(2):348-56. PubMed ID: 12112004
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
[TBL] [Abstract][Full Text] [Related]
20. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
Uyama M; Sato MM; Kawanami M; Tamura M
Genes Cells; 2012 Jul; 17(7):548-58. PubMed ID: 22702336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
